Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
Industry News
Blog|Jan 22 2024
Meet the Community 2: A Closer Look – Kate Walker
Community
Blog|Jan 15 2024
Meet the Community – Sam Blade
Community
Blog|Jan 8 2024
Meet the Community – Tihana Prelevic
Community
Blog|Dec 18 2023
Meet the Community 2: A Closer Look – Esteban Luis Grieb